Search results for "infarction"

showing 10 items of 1208 documents

Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED Trial

2016

Abstract BACKGROUND The role of branched-chain amino acids (BCAAs) in cardiovascular disease (CVD) remains poorly understood. We hypothesized that baseline BCAA concentrations predict future risk of CVD and that a Mediterranean diet (MedDiet) intervention may counteract this effect. METHODS We developed a case-cohort study within the Prevención con Dieta Mediterránea (PREDIMED), with 226 incident CVD cases and 744 noncases. We used LC-MS/MS to measure plasma BCAAs (leucine, isoleucine, and valine), both at baseline and after 1 year of follow-up. The primary outcome was a composite of incident stroke, myocardial infarction, or cardiovascular death. RESULTS After adjustment for potential conf…

0301 basic medicineMaleRiskmedicine.medical_specialtyMediterranean dietClinical BiochemistryPopulationSistema cardiovascular -- Malalties030204 cardiovascular system & hematologyDiet MediterraneanBioquímica i biotecnologiaArticleCohort Studies03 medical and health sciences0302 clinical medicineInternal medicinemedicineEstà en blancHumansMyocardial infarctioncardiovascular diseaseseducationStrokeAgededucation.field_of_studyBioquímica y tecnologíabusiness.industryIncidenceBiochemistry (medical)Hazard ratioConfoundingCase-control studymedicine.diseaseSurgeryBiochemistry and technology030104 developmental biology0009-9147Cardiovascular DiseasesCase-Control StudiesMultivariate AnalysisCardiologyFemalebusinessAmino Acids Branched-ChainCohort study
researchProduct

Homocysteine concentration in coronary artery disease: Influence of three common single nucleotide polymorphisms.

2017

Whether single nucleotide polymorphisms (SNPs) of homocysteine metabolism enzymes influence the rate of cardiovascular (CV) events in coronary artery disease (CAD) patients remains controversial.In this analysis, 1126 subjects from the AtheroGene study with CAD and 332 control subjects without known CAD were included. The following SNPs were investigated: methylentetrahydrofolate reductase (MTHFR-C667T), methionin synthetase (MS-D919G), and cystathionin beta synthetase (CBS-I278T). The endpoint was the combination of cardiovascular death, stroke, and non-fatal myocardial infarction (N = 286). The median follow-up time was 6.4 years. Kaplan-Meier curve analysis showed an increasing event rat…

0301 basic medicineMaleTime FactorsHomocysteineEndocrinology Diabetes and MetabolismMyocardial InfarctionMedicine (miscellaneous)Coronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyReductaseGastroenterology5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCoronary artery diseasechemistry.chemical_compound0302 clinical medicineGene FrequencyRisk FactorsMyocardial infarctionStrokeHomocysteineGeneticsNutrition and DieteticsbiologyHomozygoteMiddle AgedStrokePhenotypeArea Under CurveDisease ProgressionFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyHeterozygoteCystathionine beta-SynthaseSingle-nucleotide polymorphismPolymorphism Single NucleotideRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseGenetic Association StudiesMethylenetetrahydrofolate Reductase (NADPH2)AgedProportional Hazards ModelsChi-Square DistributionCurve analysismedicine.disease030104 developmental biologychemistryROC CurveMethylenetetrahydrofolate reductaseCase-Control Studiesbiology.proteinBiomarkersNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

miRNAs and sports: tracking training status and potentially confounding diagnoses.

2016

Background The dependency of miRNA abundance from physiological processes such as exercises remains partially understood. We set out to analyze the effect of physical exercises on miRNA profiles in blood and plasma of endurance and strength athletes in a systematic manner and correlated differentially abundant miRNAs in athletes to disease miRNAs biomarkers towards a better understanding of how physical exercise may confound disease diagnosis by miRNAs. Methods We profiled blood and plasma of 29 athletes before and after exercise. With four samples analyzed for each individual we analyzed 116 full miRNomes. The study set-up enabled paired analyses of individuals. Affected miRNAs were invest…

0301 basic medicineMalemedicine.medical_specialtyConfounding Factors (Epidemiology)610Physical exerciseDiseaseBioinformatics796 Athletic and outdoor sports and gamesGeneral Biochemistry Genetics and Molecular Biology79603 medical and health sciences610 Medical sciences MedicinemedicineCluster AnalysisHumansGene Regulatory NetworksMyocardial infarctionExercise physiologyExerciseMedicine(all)Principal Component AnalysisbiologyAthletesbusiness.industryBiochemistry Genetics and Molecular Biology(all)ResearchGene Expression ProfilingConfoundingConfounding Factors EpidemiologicResistance TrainingGeneral Medicinemedicine.diseasebiology.organism_classificationGene expression profilingMicroRNAs030104 developmental biologyPhysical therapyErratumbusinessSportsJournal of translational medicine
researchProduct

Short-term Changes in Gal 3 Circulating Levels After Acute Myocardial Infarction.

2016

Background and Aims Galectin 3 (Gal 3) is a β-galactoside-binding lectin known to play a part in inflammation, adverse remodeling and fibrosis. Gal 3 seems to be linked to atherogenesis and Coronary Artery Disease (CAD), but less is known about the relationship between Gal 3 and acute myocardial infarction (AMI). The aim of the present study is to assess circulating levels of Gal 3 after AMI and to evaluate short-term changes of the biomarker within 5 days from the acute event. Methods Two hundred fifteen confirmed AMI patients (125 STEMI, M/F = 2.8; mean age: 65.4 ± 13.8 years) were enrolled in the present study; two blood samples were collected from each patient: first, within 1 h from ad…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsGalectin 3Myocardial InfarctionInflammationCoronary Artery Disease030204 cardiovascular system & hematologyAMICoronary artery disease03 medical and health sciences0302 clinical medicineFibrosisInternal medicineMedicineHumansCADcardiovascular diseasesMyocardial infarctionPlaqueAgedInflammationbusiness.industryMedicine (all)Mean ageGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyGalectin-3ImmunologyCardiologyBiomarker (medicine)Femalemedicine.symptombusinessBiomarkersArchives of medical research
researchProduct

Bi-layered polyurethane – Extracellular matrix cardiac patch improves ischemic ventricular wall remodeling in a rat model

2016

As an intervention to abrogate ischemic cardiomyopathy, the concept of applying a temporary, local patch to the surface of the recently infarcted ventricle has been explored from a number of design perspectives. Two important features considered for such a cardiac patch include the provision of appropriate mechanical support and the capacity to influence the remodeling pathway by providing cellular or biomolecule delivery. The objective of this report was to focus on these two features by first evaluating the incorporation of a cardiac extracellular matrix (ECM) component, and second by evaluating the impact of patch anisotropy on the pathological remodeling process initiated by myocardial …

0301 basic medicineMaterials scienceAngiogenesisPolyurethanesBiophysicsMyocardial IschemiaInfarctionBiocompatible MaterialsBioengineeringCeramics and Composite02 engineering and technologyCardiac ECMBiomaterialsExtracellular matrixRats Sprague-Dawley03 medical and health sciencesVentricular Dysfunction LeftAbsorbable ImplantsMaterials TestingmedicineAnimalsMyocardial infarctionCardiac patchIschemic cardiomyopathyTissue ScaffoldsVentricular RemodelingVentricular wallHydrogelsRecovery of Function021001 nanoscience & nanotechnologymedicine.diseaseBiomaterialExtracellular MatrixRatsCompliance (physiology)Electrospun scaffold030104 developmental biologymedicine.anatomical_structureTreatment OutcomeBiophysicVentricleRats Inbred LewMechanics of MaterialsCeramics and CompositesFemale0210 nano-technologyStructure - functionBiomedical engineering
researchProduct

Sca-1+cardiac fibroblasts promote development of heart failure

2018

The causative effect of GM-CSF produced by cardiac fibroblasts to development of heart failure has not been shown. We identified the pathological GM-CSF-producing cardiac fibroblast subset and the specific deletion of IL-17A signaling to these cells attenuated cardiac inflammation and heart failure. We describe here the CD45- CD31- CD29+ mEF-SK4+ PDGFRα+ Sca-1+ periostin+ (Sca-1+ ) cardiac fibroblast subset as the main GM-CSF producer in both experimental autoimmune myocarditis and myocardial infarction mouse models. Specific ablation of IL-17A signaling to Sca-1+ periostin+ cardiac fibroblasts (PostnCre Il17rafl/fl ) protected mice from post-infarct heart failure and death. Moreover, Postn…

0301 basic medicinePathologymedicine.medical_specialtyMyocarditisIschemic cardiomyopathymedicine.medical_treatmentImmunologyInflammationCD29030204 cardiovascular system & hematologyBiologyPeriostinmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCytokineHeart failurecardiovascular systemmedicineImmunology and AllergyMyocardial infarctionmedicine.symptomEuropean Journal of Immunology
researchProduct

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease.

2015

Background: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1. Methods: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported. Results: In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0…

0301 basic medicinePlacental growth factorMalemedicine.medical_specialtyClinical BiochemistryCoronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyPregnancy ProteinsCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryNatriuretic Peptide BrainmedicineHumansMyocardial infarctionPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Proportional hazards modelbusiness.industryBiochemistry (medical)Hazard ratioMiddle Agedmedicine.diseasePrognosisPeptide FragmentsVascular endothelial growth factor030104 developmental biologyEndocrinologychemistryCohortCardiologyFemalebusinessSoluble fms-like tyrosine kinase-1Follow-Up StudiesBiomarkers in medicine
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Type 2 Myocardial Infarction: A Geriatric Population-based Model of Pathogenesis

2019

International audience; Distinction between type 2 myocardial infarction (T2MI), defined as an imbalance between oxygen supply and demand without atherothrombosis, and type 1 myocardial infarction (T1MI), due to plaque disruption, is often a clinical challenge in frail elderly patients. We aimed to identify the characteristics and underlying causes of T2MI using a comprehensive geriatric approach. From a multicentre population-based prospective study in coronary care units, we adjudicated 4572 consecutive patients hospitalized for an acute T1MI or T2MI, according to the 3rd universal definition and a prespecified geriatric model of T2MI pathogenesis. In total, 3710 (81%) had T1MI and 862 (1…

0301 basic medicineRiskmedicine.medical_specialtyrespiratory tract infectionPopulationOutcomesLower riskOrginal ArticlePathology and Forensic Medicinetype 2 myocardial infarctionPathogenesis03 medical and health sciences0302 clinical medicineInternal medicineMedicineDiseaseMyocardial infarctionMortalityProspective cohort studyeducationFeatureseducation.field_of_studybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyVaccinationRespiratory infectionaortic stenosisCell Biologymedicine.diseaseanemia3. Good healthStenosis030104 developmental biologyHeart failureCardiologyNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgerytachyarrhythmia pathophysiology
researchProduct

Coronary Serum Obtained After Myocardial Infarction Induces Angiogenesis and Microvascular Obstruction Repair. Role of Hypoxia-inducible Factor-1A.

2017

Microvascular obstruction (MVO) exerts deleterious effects following acute myocardial infarction (AMI). We investigated coronary angiogenesis induced by coronary serum and the role of hypoxia-inducible factor-1A (HIF-1A) in MVO repair.Myocardial infarction was induced in swine by transitory 90-minute coronary occlusion. The pigs were divided into a control group and 4 AMI groups: no reperfusion, 1minute, 1 week and 1 month after reperfusion. Microvascular obstruction and microvessel density were quantified. The proangiogenic effect of coronary serum drawn from coronary sinus on endothelial cells was evaluated using an in vitro tubulogenesis assay. Circulating and myocardial HIF-1A levels an…

0301 basic medicineSerummedicine.medical_specialtyAngiogenesisSwineSus scrofaMyocardial InfarctionNeovascularization Physiologic030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalscardiovascular diseasesMyocardial infarctionLigationbusiness.industryEndothelial CellsGeneral Medicinemedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunit030104 developmental biologyHypoxia-inducible factorsCoronary OcclusionMicrovesselsCardiologyFemalebusinesshuman activitiesRevista espanola de cardiologia (English ed.)
researchProduct